A randomised trial of pulsed intravenous methylprednisolone for severe ocular pemphigoid

Not Applicable

Completed

• Conditions: Ocular mucous membrane pemphigoid; Skin and Connective Tissue Diseases; Bullous disorders

• Registration Number: ISRCTN51714283
• Lead Sponsor: Moorfields Eye Hospital NHS Foundation Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-01-29
• Last Update Posted: 24 July 2017

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

1. Patients with clinical features consistent with ocular mucous membrane pemphigoid
2. Patients with bilateral or unilateral ?moderate? (grade 3) or ?severe? (grade 4) ocular inflammation, with or without limbitis (i.e. oedema and increased vascularity along the limbus)
3. Patients may already be receiving non-cyclophosphamide immunosuppression

Exclusion Criteria

1. Patients currently receiving cyclophosphamide
2. Patients with other causes of progressive conjunctival scarring (drug-induced pemphigoid with negative direct immunofluorescence biopsy, atopic keratoconjunctivitis, Sjogren?s syndrome, Stevens Johnson syndrome, chemical injury)
3. Active secondary malignancy
4. HIuman immunodeficiency virus (HIV) infection
5. Pregnancy or breastfeeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified